Analytical Data
-
Gene name
LIV-1/SLC39A6
-
简介
LIV-1/SLC39A6 is a zinc influx transporter that regulates zinc homeostasis and induces epithelial-mesenchymal transition (EMT). Used in conjunction with SLC39A10, it can promote cellular zinc absorption and trigger EMT. LIV-1/SLC39A6 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived LIV-1/SLC39A6 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Application
-
Alternative Names
SLC39A6; LIV-1; ZIP6; Zinc transporter ZIP6; ZIP-6
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13433-1
-
Expression Region
F29-W325
-
Molecular Weight
55-65 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LIV-1, also known as SLC39A6, is a member of the solute carrier family of transporters that plays a crucial role in cellular zinc homeostasis. Zinc is an essential trace element required for numerous biological processes, including enzyme function, cellular signaling, and immune response. Abnormal zinc transport has been linked to various diseases, including cancers and neurodegenerative disorders. LIV-1 is particularly notable for its involvement in breast cancer, where it has been associated with tumor progression and metastasis. Research has shown that LIV-1 expression is elevated in certain breast cancer subtypes, making it a potential target for therapeutic interventions. The study of LIV-1/SLC39A6 recombinant protein is crucial for understanding its structure-function relationship and elucidating its role in zinc transport. By generating and characterizing recombinant LIV-1, researchers aim to explore its mechanism of action, identify potential inhibitors, and ultimately pave the way for new strategies in cancer treatment and prevention. Understanding how LIV-1 interacts with zinc and other cellular components could also provide insights into broader physiological and pathological processes, enhancing our knowledge of zinc transporter networks and their implications in health and disease.
